Carl J Hauser

US Patent:

20080032925, Feb 7, 2008

Filed:

Jan 26, 2007

Appl. No.:

11/627891

Inventors:

Carl Hauser - Boston MA, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - New Brunswick NJ

International Classification:

A61K 38/38
A61K 31/397
A61K 31/56
A61P 37/00
A61K 31/724

US Classification:

514012000, 514182000, 514210020, 514058000

Abstract:

A method for treating an immune-related disorder in a patient comprising administering an agent to the patient for altering the patient's plasma concentration of free cholesterol, wherein said agent is a non-statin agent and is administered in an amount sufficient to modulate the immune-related disorder.

US Patent:

20080280866, Nov 13, 2008

Filed:

Jul 7, 2005

Appl. No.:

11/658116

Inventors:

Carl J. Hauser - Mountainside NJ, US

International Classification:

A61K 31/555
A61K 31/425
A61P 29/00

US Classification:

514186, 514370

Abstract:

Provided is a method of treating trauma or sepsis comprising: administering an effective amount of one or both of a SOC channel-selective inhibitor or a SphK inhibitor to an animal at risk of inflammation-mediated organ damage from trauma or sepsis.

US Patent:

20120263736, Oct 18, 2012

Filed:

Dec 3, 2010

Appl. No.:

13/513137

Inventors:

Carl J. Hauser - Boston MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

C12Q 1/68
A61K 31/4706
A61P 31/00
A61K 31/7088
A61P 29/00
A61K 38/13
A61K 39/395

US Classification:

4241721, 435 615, 514 205, 514313, 514 44 R, 435 612

Abstract:

The invention provides methods for predicting the likelihood that a subject will develop a sterile inflammation or will have an increased propensity to later develop a sterile inflammation, for determining whether a subject with tissue damage should be administered an antimicrobial agent (at full or a reduced dosage) or an anti-inflammatory agent, and for treating a subject with tissue damage. In the methods, an increased ratio of the amount of mitochondrial nucleic acid or peptide to the amount of microbial nucleic acid or peptide indicates a subject that has an increased likelihood of developing a sterile inflammation or an increased propensity to later develop a sterile inflammation, or a subject that should not be administered, or that should be administered at a reduced dosage, an antimicrobial agent or one or more anti-inflammatory agents and not an antimicrobial agent. Kits for detecting mitochondrial and/or microbial nucleic acids or peptides are provided.

US Patent:

20130243794, Sep 19, 2013

Filed:

Dec 5, 2011

Appl. No.:

13/990605

Inventors:

Carl J. Hauser - Boston MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

C12Q 1/68
A61K 31/4706
A61K 38/48
A61K 38/17
A61K 39/395
A61K 45/06

US Classification:

4241721, 435 612, 424 9464, 514 205, 514313

Abstract:

The invention provides methods for determining the propensity to develop, or the presence of, one or more infection-induced illness(es). The invention further provides methods of treating an infection (e.g., bacterial infection), methods of diagnosing an infection-induced illness in a subject, and methods of predicting the future severity of one or more infection-induced illness(es). Also provided are kits for determining the likelihood or propensity of a subject to develop one or more infection-induced illness(es) and kits for diagnosing one or more infection-induced illness(es) in a subject and identifying a subject as having an increased risk of later developing one or more severe infection-induced illness(es).